The perspective of an innovative new concept integrating tissue-engineering techniques with an established surgical technique is described. The focus is primarily on a one-step surgical procedure using adipose tissue-derived mesenchymal stem cells, a calcium phosphate scaffold as a carrier, and a bioresorbable polymer cage to facilitate spinal interbody fusion. We address the harvesting and processing of clinically relevant quantities of adipose tissue-derived mesenchymal stem cells, triggering of these stem cells toward lineage-specific differentiation, seeding of the triggered stem cells on a bioresorbable scaffold, and implantation of the resulting tissue-engineered construct. The integrated steps can be accomplished within one surgical procedure in a surgical theater. Although the proposed concept has been developed for spinal fusion, potential application in other surgical disciplines is presumed realistic.
CELL SOURCES
Cells used in regenerative medicine can be obtained from various sources. Stem cells or progenitor cells (regenerationcompetent cells) are recruited from the tissue surrounding the implanted tissue construct or can be harvested from tissue that containsstemcells,suchas bone marrow, skin, muscle,and adipose tissue. 3 In general, the number of stem cells in any given tissue compartment is low. For example, the stem cell incidence in bone marrow is estimated to be about 1 per 10 5 cells, 4 and other compartments contain even lower stem cell numbers. A quote from the National Institutes of Health, May 2000, addressed this aspect: ''Given the enormous potential of stem cells to the development of new therapies for the most devastating diseases, when a readily available source of stem cells is identified, it is not too unrealistic to say that this research will revolutionize the practice of medicine and improve the quality of life.'' Adipose tissue is such a source, capable of meeting this challenge. Adipose tissue has several advantages over bone marrow, such as easy accessibility; minimal morbidity upon harvest; that clinically relevant stem cell numbers can be extracted from adipose tissue isolates, potentially eliminating the need for in vitro expansion; and higher stem cell proliferation rates than bone marrow mesenchymal stem cells (BM-MSCs). 5 Adipose tissue-derived mesenchymal stem cells (AT-MSCs) show potential for multiple differentiation (i.e., they differentiate in vitro and in vivo towards adipogenic, osteogenic, chondrogenic, myogenic, ligamentous, and probably, neurogenic, endothelial, hematopoietic and cardiomyogenic phenotypes).
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CHALLENGE OF A SINGLE SURGICAL PROCEDURE
Based on the current knowledge of tissue-engineering technology and adipose tissue stem cell technology in particular, we have formulated an innovative surgical concept that has been beyond reach so far. The main goal is to integrate tissue-engineering technology with established surgical interventions, or those that have yet to be developed, in a single surgical procedure. Our proposed innovative concept, as outlined in Figure 2 , uses off-the-shelf bioresorbable Concept of a one-step surgical procedure. The surgery starts with harvesting of the adipose tissue followed by a split procedure. The surgeon continues the surgery, whereas the tissue engineer isolates the stem cell-containing cell population from the adipose tissue, treats the cells to induce differentiation into the proper phenotype, and seeds the stimulated cells on the scaffold. The surgeon then implants the scaffold containing the stem cells and finishes the surgery. The whole procedure takes 2.5 hours.
2 materials and easily accessible autologous MSCs from adipose tissue, harvested with minimally invasive techniques and in a clinically relevant yield. This approach will allow restoration of damaged tissues using tissue-engineering concepts without any foreign materials remaining in situ over the long term. Not only is this concept cost effective, it is also beneficial to the patient, because the use of expensive recombinant growth factor(s) is reduced to a minimum, a second surgical intervention is avoided, and expensive contamination-sensitive stem cell expansion and specialized laboratories are not needed. In addition, this concept may reduce donor site morbidity resulting from graft harvesting. As a proof of principle, the proposed concept as described above has been validated for application in posterior lumbar interbody fusion (PLIF), also referred to as spinal fusion. PLIF surgery usually consists of decompression of the neural elements, reaming of the intervertebral disc and vertebral end-plates, and insertion of one or two cages filled with autologous bone graft harvested from the iliac crest in the intervertebral disc space created. 17 The patient would substantially benefit if a combination of a synthetic scaffold and AT-MSCs harvested with minimal discomfort in high quantities, as proposed in our concept, replaced iliac crest bone, because iliac crest bone harvesting results in temporary or persistent donor site morbidity in 10% to 30% of cases for 2 years or longer. [18] [19] [20] In our experimental surgical approach, subcutaneous adipose tissue is harvested at the surgical site immediately after the skin incision is made. The surgeon then continues with the surgical procedure while the tissue engineer processes the adipose tissue, isolates the stem cells, stimulates the stem cells with biologics (bio-inductive agents), and seeds the triggered stem cells on the scaffold. Implantation of a bioresorbable cage filled with the stem cell-seeded scaffold in the spine completes the procedure. This procedure has been verified in vivo using a well-established goat spinal fusion model, 17, [21] [22] [23] [24] and studies translating the procedure into the clinic are currently ongoing.
PHASE I/II: ISOLATION AND PURIFICATION OF ADIPOSE STEM CELLS
AT-MSCs can be isolated and processed from different species (reviewed by 25 ). The most commonly used method has been described by Zuk et al., 15 who used collagenase digestion and centrifugal enrichment of the stem cell--containing fraction, the so-called stromal vascular fraction (SVF). SVF consists of a heterogeneous mixture of cells, including endothelial cells, smooth muscle cells, pericytes, fibroblasts, mast cells, and pre-adipocytes. 15 SVF, like bone marrow, harbors a population of multipotent AT-MSCs. 15 The frequency and yield of these AT-MSCs, as estimated by applying clonogenic assays for fibroblastoid-like colonies, is in the order of 1% to 3% of the nucleated cells in humanssome 100 to 300 times as high as in bone marrow (e.g. 26, 27 ). Oedayrajsingh-Varma et al.
28 used limiting dilution assays to determine frequency and yield of AT-MSCs and found that processing of resection material instead of (tumescent) liposuction aspirate increased the stem cell frequency to 6.3% independent of the site (abdomen, hip/thigh region, back, or mamma tissue) from which the adipose tissue was obtained.
Differences and similarities exist between BM-MSCs and AT-MSCs. The general consensus is that freshly isolated stem cells from both bone marrow and adipose tissue are positive for CD10, CD13, CD29, CD44, CD49e, CD90, CD105, CD166, and human leukocyte antigen (HLA)-ABC and negative for CD31, CD45, and HLA-DR. 25, [27] [28] [29] Controversy exists for other markers such as CD34 and Stro-1, which is likely due to differences in stem cell passages affecting marker expression at the moment of marker analysis. For example, CD34 surface marker expression was lacking in passaged cells, 25, 30 whereas freshly isolated SVF showed initial high CD34 expression, which progressively declined. 27, 28, 31, 32 The population of AT-MSCs showing the consensus surface phenotype as described above were the cells that differentiated along the chondrogenic, osteogenic, adipogenic, and myogenic pathways.
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PHASE III: STIMULATION OF STEM CELLS
Stem cell differentiation studies are usually performed in vitro, with the active compound being continuously present (e.g. 9, 15, 33 ). For our concept ( Fig. 2 ), we developed a new strategy to induce differentiation of AT-MSCs toward the desired phenotype within a short time frame of only 15 min. Until recently, only a viral-based approach could induce stem cell differentiation within a short period of 2 h. In this approach, cells are transduced within 2 h with an adenovirus expressing the osteogenic growth factor bone morphogenetic protein-2 (BMP-2). 34 However, gene therapy approaches are associated with safety concerns, and therefore the choice for recombinant proteins to induce cell differentiation is favorable.
We hypothesized that binding of growth factors to cell surface receptors occurs within minutes, thus fitting within the desired time frame of 15 min for induction of cell differentiation. We tested whether the addition of 10 ng/mL BMP-2 or BMP-7, also known as osteogenic protein-1 (OP-1), for a duration of 15 min only could stimulate the differentiation of freshly isolated SVF cells along the osteogenic or chondrogenic pathway (Figure 3) . We found that BMP-2 induced an osteogenic phenotype, whereas BMP-7 induced a more chondrogenic phenotype within 4 days. In contrast, 4 days of continuous incubation with the same dosage of BMP-2 or BMP-7 did not affect osteogenic or chondrogenic gene expression. 10 This implies that a short stimulation burst period by a growth ADIPOSE STEM CELLS IN REGENERATIVE MEDICINE 3 factor might be more effective at inducing stem cell differentiation than continuous application of the growth factor.
PHASE IV: SEEDING OF STEM CELLS ON SCAFFOLDS
A vast amount of scaffold biomaterials for spinal fusion is currently available (reviewed by 35, 36 ). These scaffolds (e.g., natural and synthetic polymers such as collagens, alginate, chitosan, and poly-lactic-acid and poly-glycolic-acid polymers, as well as natural and synthetic calcium phosphate compounds) vary widely with respect to their geometry, porosity, stiffness, surface characteristics, and composition.
We used a biphasic calcium phosphate (BCP) scaffold, consisting of a 60:40 mixture of hydroxyapatite and ß-tricalcium phosphate and with a 200-to 400-mm pore size and 150 mm interconnective pores (Medtronic, Memphis, TN). These pore sizes promote neo-vascularization and intramembranous bone formation, whereas smaller pore sizes (90-120 mm) primarily induce endochondral bone formation. 37 Fluorescence and scanning electron microscopy revealed that AT-MSCs distribute rapidly and evenly throughout the BCP granules (Figure 4) . AT-MSCs attach to the scaffold within 10 min (Fig. 4A-C) , stretch within 30 min (Figure 4D-F) , and proliferate within a couple of days in the scaffold (Figure 4G-I ).
PHASE V: IN VIVO IMPLANTATION OF STEM CELL-CONTAINING CONSTRUCTS
The BCP scaffold seeded with AT-MSCs was subsequently used as filling material for bioresorbable poly-lactic acid-based interbody cages (Fig. 5A) . These bioresorbable cages have been used successfully for lumbar spinal fusion in a goat model. [21] [22] [23] [24] 38 The potential benefits of bioresorbable cages were also shown in sheep 39 and humans (reviewed by 40, 41 ). Here, we used 70/30 poly-(L,DL)-lactic acid cages ( 42 ; for a review on polylactides, see 43 ). Cages were positioned between two vertebrae, as illustrated in Figure 5B . Cellular retention of fluorescently labeled SVF cells was shown at 4 days (Fig. 5C ) but not at 28 days follow-up, which is most likely due to proliferation and therefore dilution of the intensity of the fluorescent signal. At 28 days follow-up, active bone formation by osteoblasts and resorption of scaffold material by osteoclasts were observed (Fig. 5D ).
OUR ONE-STEP SURGICAL PROCEDURE CONCEPT IN RELATION TO OTHER SPINAL FUSION METHODOLOGIES
The data presented here show the feasibility of a one-step surgical procedure using AT-MSCs, a calcium phosphate scaffold as a carrier, and a bioresorbable polymer cage to facilitate spinal interbody fusion. The whole procedure can be accomplished within a time frame of 2 to 2.5 hours, depending on whether a growth factor induction step is included. The time needed for processing the AT-MSCs can likely be reduced by using automated adipose tissueprocessing devices within the laboratory and in the clinic, with concomitant improvement of the reproducibility of the amount and quality of the cells recovered. The introduction of these stem cell-isolation devices is expected soon (e.g., see the Cytori website: www.cytoritx.com). The ultrashort induction period available for ex vivo growth factor stimulation (15 min) appeared to be sufficient to induce differentiation of the AT-MSCs toward the osteogenic or chondrogenic lineage . Rapid adherence of AT-MSCs to the BCP scaffold could be demonstrated (Fig. 4) , as well as retention of the cells within the cage after 4 days in situ and active bone formation and scaffold resorption at 28 days follow-up (Fig. 5) .
The proposed concept may provide a solution for some of the problems encountered in currently employed spinal fusion techniques.
Non-resorbable cages
When assessing long-term clinical outcome of spinal fusion using non-resorbable interbody cages, a greater incidence of revision procedures has been observed, especially in multi-level fusions. Complications with these cages Dashed line, T/C ¼ 1 (no effect). Real-time polymerase chain reaction data were normalized for 18S expression. * Significant effect of growth factor, p < 0.05 4 HELDER ET AL. include stress-shielding, implant subsidence, particle release, migration, extrusion, pseudoarthrosis, and infection. [44] [45] [46] [47] [48] [49] Disadvantages of non-resorbable cages are the permanent presence of a foreign body and the fact that they are not radiolucent, which hampers radiological assessment of fusion. Bioresorbable cages may overcome these drawbacks, because they are radiolucent, their stiffness is comparable to that of bone, and they resorb over time (reviewed by 43 ).
Osteoinductive grafts
Several types of osteoinductive grafts can be identified (i.e. autologous or allograft bone, scaffolds combined with growth factor(s), scaffolds with regeneration-competent (stem/progenitor) cells, scaffolds with genetically modified cells (e.g., transduced with growth factor-expressing vectors), scaffolds loaded with gene constructs (gene-activated matrices), and combinations thereof).
The problems associated with the harvesting of autologous iliac crest bone include donor site morbidity (e.g., hematoma, chronic pain, fractures) in up to 30% of cases, 18, 20 limited availability, and a second surgical incision. Alternatively, local ''waste'' bone obtained after spinal decompression might be used, but quantity and quality of the recovered bone is variable. 50, 51 Allograft bone is also frequently used as graft material for posterolateral fusions as well as intervertebral spinal fusions. However, allograft bone has an associated risk of transmitting viral diseases and induction of immune responses (reviewed in 35 ). Because our concept replaces autograft with a stem cell-synthetic scaffold combination, iliac crest donor site morbidity is circumvented.
Scaffolds combined with growth factors have received growing attention in recent years. Preclinical studies have demonstrated induction of fusion by growth factors such as GDF-5, 52 recombinant human BMP-4, 53 a combination of insulinlike growth factor-1 and transforming growth factor-ß1, 54, 55 and autologous growth factors. 56 However, the preclinical [57] [58] [59] [60] and clinical application [61] [62] [63] [64] [65] [66] [67] of the recombinant human BMP-2 and BMP-7 (reviewed by 68 ) boosted the use of growth factors in spinal fusion in particular. BMPs act biphasically; first, BMPs recruit stem or progenitor cells from the surrounding tissue using chemotaxis, and second, BMPs induce the differentiation cascade in these cells. Both BMPs are applied in mg amounts, which is approximately one million times the physiological concentration. Dosages of 1 mg/mL or more result in severe cell 
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toxicity in vitro (unpublished results). Initial reports of clinical studies indicated outcomes for BMP-mediated spinal fusion that were similar or superior to autograft, but recent reports also point to adverse effects, such as bone formation at undesired locations (e.g., causing spinal cord and nerve root compressions), osteolysis surrounding the fusion area, and possible adverse tissue reaction ( 69 ; reviewed in 68 ). Our concept avoids the complications indicated above in two ways. In our concept, the stem cells are applied in situ within the cage at the moment of implantation, thus surpassing the recruitment phase of stem cells from the surrounding tissue. Second, by exposing the stem cells ex vivo to ng dosages instead of the million times higher mg dosages employed in current clinical studies (see above), risks of adverse effects by exposure to excessive concentrations of BMP-2 and high treatment costs can be avoided.
Osteoconductive scaffolds may be modified into osteoinductive or bioactive scaffolds using the addition of growth factors. However, no osteoconductive material or osteoinductive stimulus will be effective in the absence of osteogenic cells. Therefore, current approaches frequently combine scaffolds with regeneration-competent cells (BM-MSCs, ATMSCs, or other stem cells) that may or may not be treated with differentiation agents. 70 -73 The most common source of regeneration-competent cells is still bone marrow harvested from the sternum or the iliac crest or from vertebral bone. 74, 75 To increase the yield of BM-MSCs, MSC expansion techniques are used. Culture-expanded BM-MSCs have shown positive spinal fusion outcome in animal models [70] [71] [72] [73] but have not been evaluated in clinical studies. 76 Disadvantages include a second surgery requirement for procurement of bone marrow, high costs, the need for availability of Good Manufacturing Practice-qualified laboratories and personnel, specialized culture conditions, and risk of contamination. 76, 77 We and others have shown that clinically relevant stem cell numbers could be extracted from adipose tissue, thereby eliminating the need for in vitro expansion. 15, 28 This, together with the higher stem cell proliferation rates observed in AT-MSCs than in BM-MSCs 5 , favors adipose tissue over bone marrow.
Combinations of scaffolds with genetically modified cells that were (conditionally) overexpressing growth factors are currently under evaluation (e.g. 34, 78, 79 ). Introduction of plasmids or other vectors can be accomplished in vitro using transfections and transductions and in vivo using geneactivated matrices. 80, 81 These matrices are scaffolds into which vectors are incorporated. During resorption of the matrix, these vectors are taken up and expressed by the cells, thereby ensuring prolonged expression of the growth factor. However, there are safety concerns about gene therapeutic approaches, such as the unpredictable kinetics of protein production in vivo and the unknown fate of the BMPtransfected cells. 82 In addition, expensive specialized virus production facilities and rigid quality control are required for clinical application. Until these concerns have been addressed, gene therapeutic approaches will not be readily applicable for non-life threatening diseases such as degenerative disc disease, herniated discs, and spondylolisthesis.
CONCLUSIONS AND FUTURE PERSPECTIVE
Several issues need to be addressed for the proper evaluation of the concept of a one-step surgical procedure in general, although it is promising for application in spinal fusion. For example, the optimal number of stem cells to be applied has to be determined (does ''the more the better'' rule of thumb always apply for tissue engineering, or could this eventually lead to adverse effects?). The selection of the optimal scaffold and the evaluation of other differentiationinducing growth factors than BMP-2 and BMP-7 need further investigation. The implications of the heterogeneity of the freshly isolated cell population, which contains not only AT-MSCs, but also smooth muscle cells, pericytes, fibroblasts, and endothelial cells, needs to be assessed. Bone formation will not occur without neovascularization, 83 a process for which the heterogeneous mixture of cells could function as building blocks. Recently, AT-MSCs were shown to secrete multiple angiogenic and anti-apoptotic cytokines supporting tissue regeneration and minimizing tissue damage, 84 which provide new insight into the mechanisms of action of AT-MSCs in the process of tissue engineering.
The integration of tissue engineering and surgical techniques can be modified and adapted to various surgical interventions in addition to spinal fusion. Concepts can be worked out for orthopedic interventions in which bone stock deficiencies are a serious problem, such as in trauma, bone tumor surgery, and revision surgery of loosened endoprostheses. Because AT-MSCs are multipotent, the concept of a one-step surgical procedure can also be applied to other musculoskeletal and non-skeletal anatomical sites, such as degenerative disc disease, muscular dystrophy, myocardial infarction, and neurological diseases (reviewed in 26, 85 ). In the long run, the concept of a one-step surgical procedure might be adapted for so-called outpatient clinical use. For example, for treatment of degenerative disc disease, we envision the following minimally invasive procedure in the outpatient clinic: retrieval of AT-MSCs, stimulation with growth factors, and percutaneous injection of these cells into the degenerated disc. This kind of treatment modalities would be a further breakthrough in surgical discipline.
